Systematic Literature Review: Could Plasma Convalescent Prevent Death on COVID-19?

Jordan Steven Widjaja, Prawesty Diah Utami, Jeanaya Hedya Alfara Putri, Yemima Billyana Kusbijantoro


The COVID-19 pandemic is still a global health problem, and the lack of effective and efficient treatment standards is one of the causes of the high morbidity and mortality rates. One approach often used in various cases of COVID-19 is convalescent plasma therapy. The administration of convalescent plasma is one of the treatment options that are often used in cases of COVID-19 with mild, moderate, severe, chronic, and critical symptoms. The article review aims to analyze how convalescent plasma transfusion in various cases of COVID-19 can prevent death and improve clinical outcomes. The PRISMA flowchart is applied to filter the literature that meets the inclusion criteria: published articles with experimental or observational research discussing the use of convalescent plasma in COVID-19 patients; published January 2020 - March 2021. We conducted article searches through PubMed, Google Scholar, and Science Direct. Assessment of the quality of the articles using the EPHPP form, and we chose ten articles. The results of the qualitative analysis prove that convalescent plasma administration in various COVID-19 cases significantly reduces viral load, clinical improvement and prevents death in mild, moderate, and severe COVID-19s, but for terminal or critical cases, it does not show significant results. The success rate of convalescent plasma therapy is determined by the high antibody titer in plasma donors, the distance between its administration and the onset of symptoms, and the patient's baseline condition before plasma administration. Based on these results, further research is needed to determine the standard dose and method of administration of convalescent plasma referring to the varied baseline conditions of patients.


Plasma Convalescent; COVID-19; Death

Full Text:



Al-Riyami, A. Z. (2021). COVID-19 convalescent plasma: Mechanisms of action and rationale for use: A narrative review. Annals of Blood, 6, 16-6.

Alsharidah, S., Ayed, M., Ameen, R. M., Alhuraish, F., Rouheldeen, N. A., Alshammari, F. R., Embaireeg, A., Almelahi, M., Adel, M., Dawoud, M. E., Aljasmi, M. A., Alshammari, N., Alsaeedi, A., Al-Adsani, W., Arian, H., Awad, H., Alenezi, H. A., Alzafiri, A., Gouda, E. F., Askar, M. Z. (2021). COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. International Journal of Infectious Diseases, 103, 439–446.

Barone, P. and DeSimone, R. A. (2020). Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion, 60(6), 1123–1127.

Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez De Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Lane, H. C. (2020). Remdesivir for the Treatment of COVID-19 — Final Report. New England Journal of Medicine, 383(19), 1813–1826.

Bloch, E. M. (2021). Convalescent plasma and hyperimmune globulin therapy in COVID-19. Expert Review of Clinical Immunology, 17(4), 309–316.

Briggs, N., Gormally, M. V., Li, F., Browning, S. L., Treggiari, M. M., Morrison, A., Laurent-Rolle, M., Deng, Y., Hendrickson, J. E., Tormey, C. A., & Desruisseaux, M. S.

(2021). Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS ONE, 16(7), 1–15.

Choi, J. Y. (2020). Convalescent plasma therapy for coronavirus disease 2019. Infection and Chemotherapy, 52(3), 307–316.

Dai, W., Gu, H. and Hao, S. (2020). Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19. Blood Science, 2(3), 71–75.

Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J., Zhou, M., Chen, L., Meng, S., Hu, Y., Peng, C., Yuan, M., Huang, J., Wang, Z., Yu, J., Gao, X., Wang, D., Yu, X., Li, L., Yang, X. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. JAMA - Journal of the American Medical Association, 39(1), 1–7.

Franchini, M. and Liumbruno, G. M. (2021). Convalescent plasma for the treatment of severe COVID-19. Biologics: Targets and Therapy, 15, 31–38.

Garibaldi, B. T., Wang, K., Robinson, L., Zeger, S. L., Bandeen-Roche, K., Wang, M. C., Alexander, G. C., Gupta, A., Bollinger, R., Xu, Y. (2021). Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19. JAMA Network Open, 4(3), 1–14.

Gil, C., Ginex, T., Maestro, I., Nozal, V., Bararado-Gil, L., Cuesta-Geijo, M. A., Urquiza, J., Ramirez, D., Alonso, C., Campillo, N. E., Martinez, A. (2020). COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 63(21), 12359–12386.

Hacisuleyman E., Hale C., Saito Y., Blachere N.E., Bergh M., Conlon E.G., Babajew D.J.S., DaSilva J., Muecksch F., Gaebler C., Lifton R., Nussenzweig M.C., Hatziioannou T., Bieniasz P.D., and Darnell R.B. (2021). Vaccine Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine, 384(23), 2212–2218.

Horby P., Lim W.S., Emberson J.R, Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L.C., Faust S. N, Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J.K., Haynes R., Landray M.J. (2021). Dexamethasone in Hospitalized Patients with COVID-19. New England Journal of Medicine, 384(8), 693–704.

Ingraham N.E., Emran S.L., Thielen B.K., Techar K., Morris R.S., Holtan S.G., Dudley R.A., Tignanelli C.J. (2020). Immunomodulation in COVID-19. The Lancet Respiratory Medicine, 8(6), 544-546.

Li L., Zhang W., Hu Y., Tong X., Zheng S., Yang J., Kong Y., Ren L., Wei Q., Mei H., Hu C., Tao C., Yang R., Wang J., Yu Y., Guo Y., Wu X., Xu Z., Zeng L., Xiong N., Chen L., Wang J., Man N., Liu Y., Xu H., Deng E., Zhang X., Li C., Wang C., Su S., Zhang L., Wang J., Wu Y., Liu Z. (2020). Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients with Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 324(5), 460–470.

Libster R., Marc G. P., Wappner D., Coviello S., Bianchi A., Braem V., Esteban I., Caballero M. T., Wood C., Berrueta M., Rondan A., Lescano G., Cruz P., Ritou Y., Viña V. .F, Paggi D. A., Esperante S., Ferreti A., Ofman G., Ciganda A., Rodriguez R., Lantos J., Valentini R., Itcovici N., Hintze A., Oyarvide M.L., Etchegaray C., Neira A., Name I., Alfonso J., Castelo R.L., Caruso G., Rapelius S., Alvez F., Etchenique F., Dimase F., Alvarez D., Aranda S. S., Yanotti C.S., Luca J.D., Baglivo S.J., Laudanno S., Nowogrodzki F., Larrea Ramiro, Silveyra M., Leberzstein G., Debonis A., Molinos J., González M., Perez E., Kreplak N., Argüello S.P, Gibbons L., Althabe F., Bergel E., Polack F.P. (2021). Early High-Titer Plasma Therapy to Prevent Severe COVID-19 in Older Adults. New England Journal of Medicine, 384(7), 610–618.

Long H.A., French D.P. and Brooks J.M. (2020) Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Research Methods in Medicine & Health Sciences, 1(1), 31–42.

Bernal J.L, Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., Stowe J., Tessier E., Groves N., Dabrera G., Myers R., Campbell C.N.J., Amirthalingam G., Edmunds M., Zambon M., Brown K.E., Hopkins S., Chand M., Ramsay M. (2021). Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 385(7), 585–594.

Luchsinger L.L., Ransegnola B.P., Jin D.K., Muecksch F., Weisblum Y., Bao W., George P.J., Rodriguez M., Tricoche N., Schmidt F., Gao C., Jawahar S., Pal M., Schnall E., Zhang H., Strauss D., Yazdanbakhsh K., Hillyer C.D., Bieniasz P.D., Hatziioannou T. (2020). Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. Journal of Clinical Microbiology, 58(12), 1–14.

Jenkins J.M., Baillie M.S.C.K., Cleary P., Khaw F.M., Lim W.S., Makki S., Rooney K.D., Tam J.S. N.V., Beck C.R. (2015). The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. Journal of Infectious Diseases. 211(1), 80-90.

Maor Y., Cohen D., Paran N., Israely T., Ezra V., Axelrod O., Shinar E., Izak M., Rahav G., Levene N. R., Bazofin B. M., Gelman R., Dicker D., Nissimov T. B., Megged O., Dahan D., Benov A., Paz A., Edward K., Moran A., Rogowski O., Sorkine P., Mayo A., Zimhony O., Chen J. (2020). Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine, 26, 1–9.

Mehta H.B., Ehrhardt S., Moore T.J, Segal J.B., Alexander G.C. (2020). Characteristics of registered clinical trials assessing treatments for COVID-19: A cross-sectional analysis. BMJ Open, 10(6), 1–9.

Nasrallah A.A., Farran S.H., Nasrallah Z.A., Chahrour M.A., Salhab H.A., Fares M.Y., Khachfe H.H., Akl E.A. (2020). A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. Journal of Clinical Epidemiology, 125(2020), 170–178.

Omrani A. S., Zaqout A., Baiou A., Daghfal J., Elkum N., Alattar R. A., Bakdach D., Abusriwil H., Mostafa A. M., Alhariri B., Ambra N., Khatib M., Eldeeb A. M., Merenkov Z., Fawzi Z., Hmissi S. M., Hssain A. A., Coyle P. V., Alsoub H., Almaslamani M. A., Alkhal A. (2021). Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report. Journal of Medical Virology, 93(3), 1678–1686.

Permana, B., Linlin, L., Hendra, A., Juniarni, L. (2020). The Effect of Yoga Exercise on Reducing Blood Pressure Among Elderly with Hypertension: a Systematic Review. Jurnal Pendidikan Keperawatan Indonesia, 6(2), 163–170.

Psaltopoulou, T., Sergentanis, T., Pappa, V., Politou, M., Terpos, E., Tsiodras, S., Pavlakis, G., Dimopoulos, M. (2020). The Emerging Role of Convalescent Plasma in The Treatment of COVID-19. HemaSphere, 4(3), 1–16.

Salazar, E., Kuchipudi, S. V., Salazar, Eric, Kuchipudi, S.V., Christensen, P.A., Eagar, T., Yi, X., Zhao, P., Jin, Z., Long, S. W., Olsen, R.J., Chen, J., Castillo, B., Leveque, C., Towers, D., Lavinder, J., Gollihar, J., Cardona, J., Ippolito, G., Nissly, R., Bird, I., Greenawalt, D., Rossi, R.M., Gontu, A., Srinivasan, S., Poojary, I., Cattadori, I.M., Hudson, P. J., Josleyn, N.M., Prugar, L., Huie, K., Herbert, A., Bernard, D.W. Dye, J. M., Kapur, V., Musser, J.M. (2020). Convalescent Plasma Anti–SARS-CoV-2 Spike Protein Ectodomain and Receptor-Binding Domain IgG Correlate with Virus Neutralization. Journal of Clinical Investigation, 130(12), 6728–6738.

Salazar, E., Christensen, Paul A., Graviss E.A., Nguyen, D.T., Castillo, B., Chen, J., Lopez, B.V., Eager, T.N., Yi, X., Zhao, P., Rogers, J., Shehabeldin, A., Joseph, D., Masud, F., Leveque, C., Olsen, R.J., Bernard, D.W., Gollihar, J., Musser, J.M. (2020). Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer AntieSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. The American Journal of Pathology, 191(1), 1–19.

Salazar, E., Christensen, Paul A., Graviss E.A., Nguyen, D.T., Castillo, B., Chen, J., Lopez, B.V., Eager, T.N., Yi, X., Zhao, P., Rogers, J., Shehabeldin, A., Joseph, D., Masud, F., Leveque, C., Olsen, R.J., Bernard, D.W., Gollihar, J., Musser, J.M. (2020). Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. American Journal of Pathology, 190(11), 2290–2303.

Wu, Y., Hong, K., Ruan, L., Yang, X., Zhang, J., Xu, J., Pan, S., Ren, L., Chen, L., Huang, C., Shang, Y. (2020). Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study. Virologica Sinica, 35(6), 768–775.

Zhang, Y., Geng, X., Tan, Y., Li, Q., Xu, C., Xu, J., Hao, L., Zeng, Z., Luo, X., Liu, F., Wang, H. (2020). New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomedicine and Pharmacotherapy, 127(2020), 1–7.

Zhou, B., Kojima, S., Kawamoto, A., Fukushima, M. (2021). COVID-19 Pathogenesis, Prognostic Factors, and Treatment Strategy: Urgent Recommendations. Journal of Medical Virology, 93(5), 2694–2704.



  • There are currently no refbacks.

Jurnal Pendidikan Keperawatan Indonesia(JPKI) published by Indonesia University of Education. JPKI is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License

View My Stats

Office :
Nursing Department. FPOK UPI.
229, Dr. Setiabudhi Street. Bandung 40154
West Java , Indonesia
E-mail :